There is a need for an alternative to human donor corneas as the availability of good-quality tissues remains limited, with this situation potentially worsening as the population in many countries is progressively ageing. There have been numerous attempts to develop corneal equivalent as alternatives to donated human corneas as well as prostheses. In this short review, we focus on the efforts in bioengineering implants that promote regeneration by Canadian researchers, including our current team of authors. The examples of technologies developed that we describe include biomaterials that allow for partial regeneration of corneal tissue, self-assembled cornea constructs and cell-free corneal implants that promoted regeneration when evaluated in clinical trials in Europe.
The human cornea is the optically clear window of the eye and its main refractive component that focuses light to the retina allowing vision.
Thus, the optical transparency of the cornea is critical for optimal vision. Injury or diseases that cause irreversible loss of transparency lead to vision loss and eventually blindness. Globally, it is estimated that 4.9 million individuals have bilateral corneal blindness 1 while 23 million are estimated to be unilaterally cornea blind. 2 Cornea transplantation with human donor corneas is the only extensively accepted treatment to restore eyesight. In fact, human cornea is one of the most transplanted tissues worldwide, with more than 53,000 corneal grafts performed in 2013 in North America alone. 3 However, it is becoming increasingly difficult for Eye Banks worldwide to meet the growing demand for good-quality donated corneas, which is in part due to population ageing. According to the Eye Bank Association, of America, the number of corneal transplantations performed in the US has increased by 50.9 % since 2005, a number that has increased faster than the number of potential donors. 3, 4 Thus, donor tissue shortage has become a growing concern for most countries. [5] [6] [7] [8] Artificial corneas made from traditional plastics, such as the AlphaCor ® Keratoprosthesis are available, but these do not completely biointegrate into the host cornea. The Boston Keratoprostheses and osteo-odontokeratoprosthesis (OOKP) have a plastic optic but a corneal rim or tooth as the interface with the patient's remaining cornea. These two biological interfaced devices have been reported to be among the most successful prostheses, but are still reserved for end-stage disease, 9,10 as they restore only minimal function and require lifetime antibiotic therapy and immune suppression. They also increase the risk of other sight-threatening conditions, such as glaucoma, which require an additional surgical procedure, such as the placement of a shunt to alleviate eye pressure.
Currently, when a cornea requires replacement by transplantation, the pathological tissue is surgically removed and replaced by a donated human eye bank cornea that is sutured or glued in place. The overall success rate is high in many countries, such as Sweden, with rejection at only 10-15 % over the first 2 years post-operative. What is not as commonly reported is that transplantation results are still suboptimal. 
Keratoprostheses with Regenerative Capability
The traditional keratoprostheses as mentioned above have focused on replacement of minimal function to allow vision. Sheardown and co-workers have focused on keratoprostheses that have allowed partial regeneration, by modification of biomaterials with cell adhesion peptides and growth factors. 15, 16 The following are examples of biomaterials developed for use as keratoprostheses.
In Aucoin et al., 17 poly(dimethyl siloxane) (PDMS) surfaces were modified by covalent attachment of combinations of cell adhesion peptides that were derived from laminin and fibronectin. The peptides studied included the commonly studied YIGSR and its synergistic peptide PDSGR from laminin, and fibronectin-derived RGDS and PHSRN. 
Self-assembled Corneal Constructs
The team of Auger, Germain and their co-workers at the Laboratoire 
Figure 1: Slit Lamp Biomicroscopy Images of the Corneas of All 10 Patients at 4 years after Grafting with a Biosynthetic Implant
Reproduced with permission from Fagerholm et al., 2014. 23 To date, self-assembled cornea constructs have been developed that reproduce one or more layers of the human cornea. 20, 21 A tissueengineered stroma replacement was tested in cats recently and at 4 months post-operation, all grafts were stable and clear. 21 These implants were re-innervated, showing comparable touch sensitivity to pre-operation levels. Histological evaluation showed a lamellar structure similar to that of a healthy cornea.
First Demonstration of Regeneration of the Human Cornea Promoted by a Cell-free Implant
Members of our team recently published the 4-year follow-up results of a phase I clinical study where transparent biosynthetic analogues of human corneal stromal extracellular matrices, comprising carbodiimide-crosslinked recombinant human collagen type III (RHCIII), were implanted in the first 10 human patients. 22 We showed that the implants were stably integrated without immunosuppression.
Unlike donor corneas, they did not attract antigen-presenting dendritic cells (see Figure 1) . Furthermore, by mimicking the corneal ECM, they promoted in-growth of the patients' own corneal epithelial cells, nerves and stromal keratocytes to regenerate a neo-cornea (see Figure 2) . 22, 23 This was a major step in corneal transplantation as we demonstrated for the first time that the human cornea is capable of regeneration, and that biomaterials can be used to stimulate the regeneration as an alternative to donor human allografts, giving hope to patients who were not transplanted due to a severe worldwide shortage of donor tissues.
Further development of these implants included the use of riboflavin and UVA light to potentially crosslink or weld the implants into the corneas of hosts. In a study conducted by Wand et al., 24 RHCIII corneal implants were successfully crosslinked into excised porcine and rabbit eyes. While further optimisation is required to address shrinkage that was noted after crosslinking, nevertheless, in the future, this technique could help reduce suture-related complications, 
(Top row) Anterior segment optical coherence tomography (ASOCT) images of a healthy cornea, biosynthetic implant and human donor transplant by penetrating keratoplasty (PK). Areas of wound-healing activity exhibit high reflectivity (white areas). (A to O) in vivo confocal microscopy (IVCM) images. Intact epithelium of the unoperated cornea (A), regenerated corneal epithelial cells on the implant surface (B) and regenerated epithelium of the penetrating graft (C). Regenerated nerves (E) at the subbasal epithelium in an

Bioengineered Cornea Implants for High-risk Patients
The first RHCIII substitutes were implanted in non-inflamed corneas.
In order to ensure that the next generation of implants will resist the insults of inflamed eyes, including collagenases, dryness and neovascularisation, which typically lead to ulceration, melting and opacification of the graft, the RHCIII implants were reinforced. A second network of 2-methacryloyloxyethyl phosphorylcholine (MPC) crosslinked with polyethylene (glycol) diacrylate (PEGDA) was added to form an interpenetrating network. The first RHCIII-MPC implants were developed in Canada, but optimisation for clinical evaluation was conducted in Sweden. The optimised generation of RHCIII-MPC implants were tested in a pilot clinical study conducted in the Filatov Institute for Eye Diseases and Tissue Therapy, Odessa, Ukraine. Three patients with persistent ulceration and erosions of the cornea surface and who were at high risk of rejection of human donor corneas were implanted with RHCIII-MPC as tectonic grafts.
All three patients showed relief of the symptoms of pain, irritation and photophobia. The implants were still stably integrated at 9 and 12 months in the patients (see Figure 3) . Two of three patients also showed improvement in vision. 25 
Conclusion
The field of cornea regeneration is one that is active and many groups are working on the development of new technologies. We have shown how several technologies developed by Canadian researchers have now been enhanced by ongoing European research including clinical evaluation. ■
